Please note that following on from information provided to NICE by the company in November 2022, the appraisal of "Renal cell carcinoma (high risk) - atezolizumab (adjuvant) [ID5101]" was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | TA |
| ID number | 5101 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 30 October 2024 | Discontinued. Please note that following on from information provided to NICE by the company in November 2022, the appraisal of "Renal cell carcinoma (high risk) - atezolizumab (adjuvant) [ID5101]" was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 28 November 2022 | Suspended. As you will be aware the Department for Health & Social Care has asked NICE to carry out an appraisal of Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]. For information, the company have announced that the trial did not meet its primary endpoint and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 05 May 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 05 May 2022 | Topic selection. . |
| 30 March 2022 | Awaiting development |
| 30 March 2022 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual